Testing of the CRM1 inhibitors KPT-185 and KPT-251 demonstrated in vitro activity against human AML cell lines harboring various genetic alterations and in vivo efficacy in AML cell line xenotransplantation models, likely via G1 cell cycle arrest and induction of apoptosis (128, 130). This evidence concerns the gene XPO1 and acute myeloid leukemia.